versus placebo-treated patients (0.2:t 0.4) (P= 0.01). However, this difference was not clinically meaningful. No hypomanic switch episodes were observed during study phase II. Despite the limited sample size resulting in insufficient power to detect statistical significance in relapse rates or change in YM R scores between treatment conditions, these preliminary data appear to support previous observations demonstrating that initial and continuation fluoxetine monotherapy may be safe and effective for some patients with BP II or BP NOS MDE with a low manic switch rate. Current guidelines for the treatment of bipolar type II (BP II) major depressive episode (MDE) recommend using either mood stabilizer monotherapy or the combination of a mood stabilizer with a selective serotonin reuptake inhibitor (SSRI). These guidelines are the result of concern over SSRI-induced manic switch episodes. We previously showed that fluoxetine monotherapy may be effective as an initial treatment for BP II and BP NOS MDE with a low manic switch rate. We now present the results of a double-blind, placebo-substitution continuation study of fluoxetine monotherapy in BP II and BP NOS patients who have recovered from their MDE. This was a two-phase study. In study phase I, patients received open-label fluoxetine monotherapy 20 mg daily for up to 8 weeks.
Current guidelines for the treatment of bipolar type II (BP II) major depressive episode (MDE) recommend using either mood stabilizer monotherapy or the combination of a mood stabilizer with a selective serotonin reuptake inhibitor (SSRI). These guidelines are the result of concern over SSRI-induced manic switch episodes. We previously showed that fluoxetine monotherapy may be effective as an initial treatment for BP II and BP NOS MDE with a low manic switch rate. We now present the results of a double-blind, placebo-substitution continuation study of fluoxetine monotherapy in BP II and BP NOS patients who have recovered from their MDE. This was a two-phase study. In study phase I, patients received open-label fluoxetine monotherapy 20 mg daily for up to 8 weeks.
Responders with a final 17-item Hamilton Rating Scale for Depression (HAM-D) score ~ 9 were enrolled into study phase II which consisted of double-blind, placebo-substitution continuation therapy with fluoxetine 20 mg daily for up to 6 months. Outcome measures included the 17-item HAM-D and Young Mania Rating (YMR) scales. Changes in YMR scores were assessed using generalized estimating equation analysis. Relapse was assessed using Kaplan-Meier survival analysis and Fisher's exact test. In study phase 11,43% of fluoxetine-treated patients and 100% of placebo-treated patients relapsed during continuation therapy (P=0.08). The mean increase in YMR score in study phase II was slightly higher in the fluoxetine-treated patients (3.0:t 1.8)
Introduction I Bipolar type II (BP II) disorder is the most common phenotype of BP disorder (Simpson t't ol, 1993; Benazzi et 01., 1997; Akiskal and Pinto, 1999; Benazzi, 1999; Akiskal, 2003; Berk and Dodd, 2005) . Its clinical course is characterized by a preponderance of depressive episodes with a lifetime history of one or more hypomanic episodes lasting at least 4 days (Dunner et ol, 1976; Akiskal, 1996) . BP II disorder is diagnostically stable over time (Akiskal, 1996 (Akiskal, , 2003 and rarely evolves into 'BP type I (manicdepressive) disorder (Ayuso-Gutierre?; and Ramos-Brieva, 1982; Faedda et ol, 1993; Coryell et ol, 1995) . BP II disorder is often difficult to recognize, and frequently goes undiagnosed (Benazzi, 1997 , 1 <)99; Cassano et ol, 1999; Akiskal, 2003; Goldberg, 2003; Berk and Dodd, 2005) . BP II patients often do not rec<?gnize the presence of their hypomanic symptoms or, if recbgnized, they rarely Although some investigators have suggested that BP I and BP II disorders may be distinct' clinical and biochemical entities (Goodwin and Jamison, 1990») the majority of treatment studies have grouped BP I and BP II disorders together. This has resulted in a paucity of information about the most appropriate initial and continuation treatment for BP II MDE (Berk and Dodd, 2005) .
MDE do receive antidepressant monotherapy (Benazzi, 1997 (Benazzi, , 1999 Cassano et ol, 1999; Berk and Dodd, 2005) , and some studies have suggested that the rate of druginduced mania in BP II MDE may be considerably lower than previously thought (Amsterdam and Brunswick, 2003) . Although cases of SSRl-induced mania have been reported (Feder, 1990; Stoll et d, 1994; Heimann and March, 1996) , controlled clinical trials of SSRl monotherapy in BP II MDE patients have reported good efficacy and a relatively low manic switch rate (Benfield etol, 1986; Cohnetol, 1989; Simpson and DePaulo, 1991; Maj, 1997; Amsterdam et ol, 2004) . Unfortunately, many of these studies have included patients with BP I disorder as well, and many of the patients were also taking a mood stabilizer.
There is debate as to whether antidepressant therapy is even effective for BP MDE (Montgomery et al, 2000; Geddes and Goodwin, 2001; Ghaemi et al, 2004) . Several controlled trials of antidepressant add-on therapy in BP I and BP II MDE patients taking established mood stabilizer therapy have failed ~o demonstrate clear-cut antidepressant efficacy (Young etd , 2000; Nemeroff etal, 2001; Post et al, 2003) , althou~ this contention has not been a universal finding (Kupfer et al, 2001 ).
In the present study, we present data from a prospective, double-blind, placebo-substitution study of the safety and efficacy of initial and continuation fluoxetine mono therapy 20mg daily in BP II MDE and BP NOS MDE patients.
Current treatment recommendations for the use of antidepressants in BP II MDE are largely based upon the treatment approach to BP I MDE, which discourages the use of antidepressants due to concern over the risk of drug-induced manic switch episodes (Wehr and Goodwin, 1979; Wehr and Goodwin, 1987; J:lrien et aI., 1994; Boerlin et aI., 1998; Ghaemi et 01., 1999 
Methods

Study design
All subjects were provided with a detailed description of the purpose and procedures of the study in accordance with the ethical standards set forth by the Institutional Review Board of the University. All subjects provided their written informed consent before enrolling in the trial.
This was a two-phase trial. Phase I of the study consisted of all patients receiving open-label fluoxetine monotherapy 20 mg daily for 8 weeks. During this study phase, the fluoxetine dose could be reduced to 10 mg daily for adverse events during weeks 1-4 of treatment. However, the dose of fluoxetine had to be maintained at 20 mg daily during the final 4 weeks of study phase I. Efficacy and safety measures were obtained after weeks 1,2,4,6 and 8 of treatment. Remission was defined as a final 17-item Hamilton Depression Rating (HAM-D) (Hamilton, 1960) score:::; 9, or a final 17-item 'atypical symptom' HAM:-D score:::; 9 (Reimherr et ai, 1998) after week 8 of treatment. Patients with a final HAM-D score:::; 99 were eligible to be enrolled into study phase II, which consisted of randomized, double-blind, placebo-substitution, continuation treatment with fluoxetine monotherapy for 6 months. Patients randomized to fluoxetine monotherapy condition continued their dose at 20 mg daily. Patients randomized to the placebo condition were provided with identically appearing medication capsules.
The use ofSSRI monotherapyfof the treatment ofBP II MDE is an area of current con~roversy (Ghaemi et a/., 2000; Amsterdam and Brunswick, 2003; Post eta/., 2003) . Nevertheless, many patients with undiagnosed BP II During study phase II, efficacy and safety measures were obtained after weeks 2, 4, 8, 12, 16, 20 and 26 of doubleblind therapy. However, the actual measurement times varied slightly betWeen subjects and, accordingly, the resulted in YMR scores that were above zero at many visits.
actual day of measurement after the study phase II baseline visit was used for statistical anlilysis. Relapse was defined as an increase in the week 8 (!phase II baseline) 17-item HAM-D score ~ 14 plus DSM-IV criteria of MDE. Concomitant use of lorazepam 0.5-1.0 mg or chloral hydrate 250-1500 mg at bedtime was permitted for severe insomnia during study phase I (but was rarely used). All efficacy and safety measures were performed by study doctors who had undergone inter-rate:r reliability training with the 17-item HAM-D and Young Mania Rating (YMR) (Young et al, 1978) scales.
Patients receiving ineffective antidepressant therapy before enrolling in the trial had their medication discontinued for at least 7 days [14 days for a monoamine oxidase (MAO) inhibitor] before starting fluoxetine mono therapy. None of the patients were taking a mood stabilizer or an atypical neuroleptic agent immediately preceding enrollment in the study. The purpose of this lead-in period of up to 14 days was to avoid a drug interaction from previous psychotropic medication (e.g. MAO inhibitors).
Patient selection
Outpatients aged ~ 18 years, with a DSM-1V Axis I diagnosis of BP II or BP NOS disor&r and a current diagnosis of MDE were eligible for the trial. All patients had a baseline 17-item HAM-D score ~ 18. Patients were excluded from the study if they had a history of mania, psychosis, rapid cycling affective disorder with ~ 4 affective episodes in the preceding year, current alcohol or substance abuse, alcohol or substance dependence within the preceding 3 months, non-response to flu oxetirie therapy in the current MDE, or a previous sensitivity to fluoxetine. Pregnant or nursing women were excluded, as were patients with an unstable medical condition, or a serum thyrotropin le~el ~ 5 ~IU. Other exclusion criteria were the presence of any clinically significant cardiac disease, malignancy, presence of central nervous system disorder (e.g. Parkinson's disease, dementia), presence of significant hepatic or renal disease, use of chemotherapy, use of over-the-counter preparations (e.g. St. John's Wort), use of tranquilizers, barbiturates or other sedative and hypnotic medications.
Treatment procedures
Phase I of the study has been described elsewhere (Amsterdam et aI., 2004) . Patients who responded during study phase I were randomly assigned to continuation therapy with either fluoxetine 20 mg daily or placebo for up to 6 months. Double-blind study conditions were maintained until the end of the trial.
Statistical analysis
Descriptive statistics for the assessment of demographic and clinical variables included frequencies, means, medians, SDs and ranges (Table 1) . Time to relapse during double-blind treatment was compared betWeen treatment conditions using Kaplan-Meier analysis ( Fig. 1 ) and the log-rank test for equality of survival distributions. The proportion of patients who relapsed when taking fluoxetine monotherapy versus placebo was compared using Fisher's exact test. Change in YMR scores over time were assessed using generalized estimating equation (GEE) analysis that included the Evaluation and outcome procedures A complete psychiatric and medical history was obtained using the Structured Diagnostic Interview for DSM-IV (SCID) format (First et al, 1994) . All patients had a physical examination including blood pressure, pulse and weight, along with a complete blood count, blood chemistry profile, a serum pregnancy test in pre-and peri-menopausal women, urinalysis, urine drug screen and a 12-lead electrocardiogram. A listing of previous psychotropic drug treatment preceding study enrollment, and a list of concomitant medication was obtained. Outcome measures included the 28-it~m HAM-D rating (Williams, 1988) with the embedded 17-item HAM-D rating (Reimherr eo! 01., 1998) treatment condition (fluoxetine versus placebo), time (measured in days after phase II baseline), and a grouptime interaction variable in the regression model. The GEE analysis is equivalent to a regression analysis, but allows for more than one observation per subject and adjusts for any intra-subject correlation of measurements. A group-time interaction term that deviates significantly from zero would indicate that the change in YMR scores over time differs significantly for patients taking fluoxetine versus placebo. Because subjects were treated after relapse~ for a fair comparison of placebo versus fluoxetine, the GEE analysis was limited to YMR observations made up to the time of relapse. For subjects who did not relapse during double-blind therapy, all YMR scores were included in the GEE analysis. In addition, Students I-test was used to compare the mean change from each patient's study phase II baseline YMR score to their largest phase II YMR score between treatment groups. The mean changes for each group, with 95% confidence intervals, were also computed. Table 2 shows the mean YMR score (and number of patients) during study phase II together with YMR scores exceeding zero. Table 2 includes all positive YMR scores measured in phase II, including scores after relapse. Statistical analyses were conducted using STATA 8.0, with a twosided P < 0.05 considered statistically significant.
Results
Study enrollment
A total of 43 patients were enrolled into phase I of the trial. Of these, six patients (14%) were screen failures who did not receive study medication because they either withdrew their consent to participate in the study (n = 5) or were non-compliant (n = 1) with the study protocol. Thirty-seven patients received fluoxetine monotherapy: 34 had BP II MDE and three had BP NOS MDE. Of the 37 patients, 14 (37.8%) discontinued treatment before the completing study phase I: two (5.4%) for adverse events, three (8.1%) for lack of efficacy, two (5.4%) for non-compliance and seven (18.9%) who withdrew their consent. Fourteen patients responded during study phase I with a final 17-item HAM-D score ~ 9. Of these, two patients withdrew their consent to participate in the double-blind study phase, and 12 patients were randomized to continuation treatment with either fluoxetine monotherapy 20 mg daily (n = 8) or placebo (n = 4).
Patient characteristics
The clinical and demographic characteristics of the patients' samples in study phase I and study phase II are shown in Table 1 . Study phase I
Results of study phase 1 have been described previously (Amsterdam et aI:, 2004) and are briefly summarized here. Of the 37 patients in study phase 1,14 (37.8%) responded to initial fluoxetine mono therapy with a final week 8 17-item HAM-D score ~ 9. There was an overall reduction of the mean baseline 17-item HAM-D score from 21.7:t 3.9 to 14.8:t 8.3 by study week 8, using last observation carried forward analysis (P < 0.001, Wilcoxon paired sample test). A similar finding was also observed using the GEE analysis (P < 0.001). Three patients (8.1%) had an elevated YMR score on at least tWo consecutive study visits. Using a moderately conservative total YMR cut-off score of ~ 12 for the presence of hypomanic symptoms, five (13.5%) of the patients had a YMR score ~ 12 at any point during treatment. None Kaplan-Meier survival curves during continuation fluoxetine monotherapy or placebo. of the patients discontinued fluoxetjne therapy due to hypomanic symptoms.
American Psychiatric Association, 2002). This recommendation is based upon concerns arising from TCA-induced manic switch episodes (Wehr and Goodwin, 1979; Wehr and Goodwin, 1987; Prein and Rush, 1996; Montgomary et 01., 2000; Goldberg and Truman, 2003; Ghaemi et al, 2004) . In this context, a recent retrospective comparison of antidepressant treatment in 41 BP MDE patients found a substantially higher manic switch rate in the BP patients taking antidepressant mono therapy (84%) compared to BP patients taking an established mood stabilizer (32%) (Ghaemi et al, 2004) . Similarly, a recent review on the sl;lbject of antidepressant-induced mania found a 20-40% drug-induced manic and hypomanic switch rate in published BP MDE studies (Goldberg and Truman, 2003) . In these studies, manic switch episodes occurred with a similar frequency in the presence, or absence, of mood stabilizer therapy, especially in BP patients with previous drug-induced mania and in BP patients taking multiple antidepressants (Goldberg and Truman, 2003) .
Study phase II Efficacy
Twelve patients participated in the ~ndomized, doubleblind, continuation phase with either fluoxetine monotherapy (n = 8) or placebo (n = 4). Relapse of MDE during double-blind therapy was observed in 43% of fluoxetine-treated pati~nts and in 100% of placebotreated patients (P = 0.08, Fisher's exact). Although this difference did not achieve statisti4al significance, it appears to indicate a trend towards tr~atment differences between conditions. Figure 1 indicat~s that the median time to relapse was slightly snorter in the fluoxetinetreated patients compared to that observed in the placebo-treated group, although the difference was not statistically significant (P= 0.19).
Safety Table 2 displays the mean :t SD YMR scores at phase II baseline visit (week 8) and at subseq4ent phase II study visits.
Despite these cautionary recommendations, SSRI monotherapy has been used in patients with BP MDE for more than 2S years (Saletu et 01:, 1977) . Results from more recent, controlled prospective trials have confirmed these early findings and have found that SSRIs may be safe and effective for the short term a treatment of BP MDE (Benfield et 01:, 1986; Cohn et 01:, 1989; Simpson and DePaulo, 1991; Maj, 1997; Amsterdam, 1998; Grunze et al, 2000; Kupfer et 01:, 2001; Amsterdam and Brunswick, 2003) . For example, a multi-site study of citalopram as an add-on therapy for BP MDE patients who were resistant to initial 4-week mood stabilizer monotherapy found that 64% of citalopram-treated patients responded, with a only a 6.7% manic switch rate (Kupfer et 01:,2001) . By contrast, a double blind, placebo-controlled add-on study of paroxetine versus imipramine in patients with BP I MDE taking established lithium or valproic acid therapy did not demonstrate superior antidepressant efficacy compared to placebo, although this study was not adequately powered to detect a drug versus placebo difference (Nemeroff et 01:, 2001) . Similarly, Post et 01: (2003) found a relatively poor antidepressant efficacy in all BP MDE patient groups studied.
The mean change in YMR score (~ghest YMR score versus baseline YMR score) during study phase II was 3.0:t 1.8 [95% confidence interval (CI) = 1.3-4.7] for the fluoxetine condition versus 0.2:t 0.45: (95% CI = -0.4-0.8) for the placebo condition (P = 0.01, I-test). Despite the modestly higher YMR scores in the, fluoxetine-treated patients (versus the placebo group), tqis small difference was not clinically meaningful. Moreo~er, when all YMR scores were examined over time using! the GEE analysis, no difference in the rate of increase in individual YMR scores was observed between treatment conditions. Similarly, when patients were examined for YMR scores ~ 8 (a very conservative estimate of hypomanic syndrome), no patient in either treatment condition had a YRM score ~ 8. Thus, no patient in stildy phase II had a YMR score that was considered to bb clinically meaningful. None of the patients in study phase II met DSM-N diagnostic criteria for hypomanic episode. Finally, there were no treatment-related seriou$ adverse events in study phase II.
Although combination SSRI and mood stabilizer therapy may represent an advance in the treatment of BP II MDE over mood-stabilizer therapy alone (Kupfer ef ol, 2001 ), mood stabilizer therapy may also expose patients to additional side-effects (Youngefal., 2000) and the need to monitor plasma drug levels, hepatic enzyme levels and thyroid hormone levels. A recent retrospective study of more than 2000 patients found that SSRIs were equally effective in unipolar and BP MDE (Grunze ef aI., 2001) . Similarly, we observed good short-term efficacy of fluoxetine monotherapy 20 mg daily in 89 unipolar versus Discussion A recent expert clinician panel on the treatment of BP MDE concluded that the efficacy of SSRJ monotherapy, or combined SSRI and mood stabilize~ therapy, has not been established (Prien and Rush, 1 Q96 switch rate of 3.6% in 28 BP II patients and a hypomanic switch rate of 0.8% in 241 unipolar MDE patients taking fluoxetine monotherpy for 6 months. The results from the present study also suggested the presence of a low hypomanic switch rate in recovered BP II MDE patients during continuation fluoxetine monotherapy. Although we observed a slightly higher mean YMR score of 3.0:t 1.8 in the fluoxetine condition versus 0.2 :t 0.5 in the placebo condition (P = 0.01), this difference was not clinically meaningful because YMR scores ~ 16 are generally considered to define mild manic symptoms. Moreover, a longitudinal GEE analysis found no significant difference in the rate of change in YMR scores between treatment conditions during continuation therapy. Using a conservative total YMR cut-off score of ~ 8 to identify patients with mild symptoms of hypomania, we observed no patient in either treatment group with a YMR score ~ 8 during continuation therapy. Furthermore, we observed no DSM N hypomanic episodes during continuation therapy.
There are fewer data available on the efficacy and safety of SSRI monotherapy of BP II i disorder during continuation treatment. In a two-phase, multi-site, placebosubstitution study (Amsterdametal, 1998) , we examined the efficacy and safety of continuation fluoxetine monotherapy 20 mg daily after 16 months in 28 recovered BP II MDE and BP NOS MOB: patients (compared with 27 recovered unipolar MOE patients). We observed a slightly lower relapse rate in the BP (22%) versus the unipolar (33%) patients (ch~ squared = 0.5; d.f. = 1; P = not significant, Kaplan-M~ier survival) during continuation fluoxetine monotherapy.
Although, in the present st~dy, we were unable to demonstrate a statistically s!ignificant difference in relapse rates during continuatioh fluoxetine monotherapy (43%) versus placebo therapy (100%) (P = 0.08, Fisher's exact test), there was a trend towards greater relapse in the placebo-treated patients. Moreover, the relapse rate for the continuation flouxetine ~onotherapy group in the preseI:lt study was similar to the relapse rate observed in recovered unipolar patients during continuation fluoxetine mono therapy in an earlier long-term fluoxetine study .
Several caveats should be considered in the interpretation of the present data. The cohort sizes in study phase n were limited, resulting in insufficient power to detect statistical significance in relapse rates or to detect a significant difference in the rate of change in YMR scores betWeen treatment conditions during continuation therapy. This occurred despite the fact that 100% of placebotreated patients versus 43% of fluoxetine-treated patients relapsed. This lack of power resulted from an unanticipated low response rate to initial fluoxetine treatment in study phase I. It is possible that the response rate to initial fluoxetine therapy would have been higher if the treatment duration had been longer (Quitkin et al, 2003) , or if the dose of fluoxetine had been higher. However, a recent analysis by our group of 71 BP II MDE patients taking fluoxetine monotherapy up to 80 mg daily for 10 weeks found a remission rate of only 38% .
Our original estimate for treatm~nt response in phase I of the present study was 60% (after a 20% drop out for screen failures or side-effects). This would have resulted in 10 patients per treatment c~ndition during phase II double-blind therapy and would! have resulted in greater statistical power to detect pote*tial differences in group survival. However, only 14 patiemts (38%) met the HAM-D criteria of ~ 9 for response in study phase I, which resulted in smaller than expecte~ cohort samples in study phase II. Despite this shortc\)ming, our findings do suggest a substantial trend towards fluoxetine superiority over placebo during continuatIon therapy. The strict application of a P < 0.05 cut-off value for statistical significance has sometimes b~en criticized as being arbitrary and overly dependant on sample size. We would suggest that that the results of the present study, although not statistically signific~nt at the P < 0.05 level, should also be interpreted in tejrms of the actual group differences that were observed; in relapse rates during continuation therapy. We are presently conducting a larger, follow-up study to verifY what is suggested by these preliminary results.
Three patients in the present study had BP NOS MDE. These patients had a history of definite mood swings characterized by at least one episode of elevated mood with additional manic symptoms; however, these patients could not endorse an episode duration lasting at least 4 days. In this regard, the gradation between BP syndromes is often difficult to establish (Simpson et al, 1991; Benazzi, 1997; Cassano et ai, 1999; Ghaemi et al, 2001; Akiskal, 2003) . It is possible that patients with BP NOS disorder may be clinically distinct from patients with BP II disorder and that they may be less likely to experience fluoxetine-induced manic symptoms.
There is a paucity of data on the rate of manic switch episodes during long-term SSRE monotherapy of BP II disorder. In a previous double-blind, placebo-substitution study , we observed a hypomanic
We did not employ a patient-recorded daily chrono-record to identify sub-syndromal manic episodes. As a result, it is possible that we missed the presence of ultra-short or mild hypomanic episodes that occurred between study visits. As a result, the rate of hypomanic symptoms may have been higher than those detected; Furthermore, a higher fluoxetine dose may have resu1ted in a higher frequency of manic switch episodes.
Finally, we did not measure plasma lev~ls of fluoxetine and norfluoxetine, which may have prdvided additional information on the low response rate in s~udy phase I and the difference in relapse rates in study pl)ase II. However, a previous study in 839 unipolar and BP h MDE patients treated with fluoxetine monotherapy 20 ~g daily for up to 9 months found no relationship betwe~n plasma levels and initial response efficacy (Amsterdam et d, 1997) or between plasma levels and relapse rates during continuation therapy (Brunswick et ai, 2002) . Similarly, in a previous study, Brunswick et ai (2001) also observed the presence of substantial residual fluoxeti~e and norfluoxetine plasma levels in some patients many weeks after they were randomized to double-blind placebo therapy. This factor suggests that, in the presen~ trial, the fairly rapid relapse of patients in both treatmeqt conditions was not simply the result of the absence of citculating plasma concentrations of fluoxetine.
In summary, we examined the safety land efficacy of fluoxetine monotherapy 20mg daily fornp II MDE and BP NOS MDE. As reported previously (Amsterdam etal, 2004) , we observed a 38% remission rate! with a HAM-D score ~ 9, and 8.1% hypomania switch ra~e, during study phase I. During continuation therapy, 43% of fluoxetinetreated patients and 100% of placebo-1reated patients relapsed (P < 0.08). There were slightly ~ore hypomanic symptoms reported in the fluoxetine-~reated patients compared to the placebo group (P < 0.0]), although this difference was not clinically meaningf~l. Despite the limited sample size of the continuati<>n study phase resulting in insufficient power to d~tect statistical significance in relapse rates or change I in YMR scores betWeen treatment conditions, these Rreliminary data appear to support previous observations I that initial and continuation fluoxetine monotherapy mby be safe and effective for some patients with BP II Of' BP NOS MDE with a low manic switch rate. Larger-s~ale studies are needed to confirm these findings.
